Geriatrics News

Twenty-seven Alzheimer’s disease drugs in phase 3 clinical trials and eight drugs in phase 2 trials could launch in the next 5 years, according to data presented at the Alzheimer’s Association International Conference.

Goal-oriented therapy improved mood and quality of life among individuals with early-stage Alzheimer’s disease or dementia, according to data presented at the Alzheimer’s Association International Conference.

A comprehensive, individualized management program significantly improved functioning in moderate-to-severe Alzheimer’s disease, compared with memantine treatment alone or placebo, according to data presented at the Alzheimer’s Association International Conference.

Poorer sleep was associated with greater Alzheimer’s disease pathology, as indicated by cerebrospinal fluid biomarkers, according to recent findings.

Sustaining a moderate-to-severe traumatic brain injury is associated with an increased risk for dementia in the future, according to a study published in PLoS Medicine.

Peripheral and cerebral forms of microvascular dysfunction were associated with increased risk for depression, according to recent findings.

Certain factors, including mental illness, race, low income and being uninsured, were associated with a heightened risk for deciding to leave the hospital against the advice of a health care provider, according to a study published in the Journal of the American Geriatrics Society.

Neuropsychological measures demonstrated utility for detecting preclinical Alzheimer’s disease among older adults, according to study findings.

One in 10 individuals aged 65 years and older has Alzheimer’s disease/dementia, according to the Alzheimer’s Association.

Elders reporting persistent moderate-to-severe pain have an increased risk for memory decline and dementia, according to a study published in JAMA Internal Medicine.